XML 27 R11.htm IDEA: XBRL DOCUMENT v3.26.3
GOODWILL AND ACQUIRED INTANGIBLES
9 Months Ended
Sep. 30, 2026
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND ACQUIRED INTANGIBLES GOODWILL
Goodwill
Goodwill is tested annually for impairment, unless certain triggering events require an interim impairment analysis, including macroeconomic conditions, industry and market considerations, cost factors, overall financial performance, and other relevant entity-specific events and changes. These considerations are evaluated holistically to assess whether it is more likely than not that a reporting unit's carrying value exceeds its fair value. As of September 30, 2026, the Bridg platform is considered a discontinued operation and, therefore, is no longer a reporting unit. Our reporting units consist of the Cardlytics purchase intelligence platform in the U.S. (the "U.S. Cardlytics Purchase Intelligence Platform"), and the Cardlytics purchase intelligence platform in the U.K. There is no goodwill recorded within the Cardlytics purchase intelligence platform in the U.K.
The carrying amounts of goodwill as of September 30, 2026 were as follows (in thousands):
U.S. Cardlytics Purchase Intelligence Platform
Balance as of December 31, 2025
$110,305 
Impairment charge— 
Balance as of September 30, 2026
$110,305 

We have assessed the triggering event criteria along with related conditions and developments as of September 30, 2026. In connection with our interim review, as a result of a sustained decline in the company's stock price and associated market capitalization, we performed a quantitative goodwill impairment test as of September 30, 2026, and determined that the estimated fair value of the U.S. Cardlytics Purchase Intelligence Platform exceeded its carrying value. As such, no goodwill impairment
charge was recognized during the three and nine months ended September 30, 2026. Accordingly, this reporting unit has a heightened risk of future impairment and we will continue to monitor our assumptions, estimates, and market factors, including our stock price, for any future developments.
The method of determining fair values of the reporting units as of September 30, 2026 was the discounted cash flow method under the income approach, and to a lesser extent the market approach. The most significant assumptions utilized in the determination of the estimated fair value of the U.S. Cardlytics Purchase Intelligence Platform are the discount rate and forecasts of future revenues and cash flows. We prepared cash flow projections based on estimates of revenue growth rates and earnings growth rates for each reporting unit, taking into consideration historical performance and current macroeconomic, industry, and market conditions, as well as an implied control premium corroborated by market participant cost synergies and an adjustment for the fair value of third-party debt. The discount rate, which is consistent with a weighted average cost of capital that is likely to be expected by a market participant, is based upon industry required rates of return, including consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse changes in the macroeconomic environment and volatility in the equity and debt markets.
Although no goodwill impairment charge was recognized as of September 30, 2026, the U.S. Cardlytics Purchase Intelligence Platform remains susceptible to future impairment risk. Future changes in key assumptions, failure to achieve forecasted operational results, or a sustained decline in our stock price could result in a future goodwill impairment charge.